Galectin Therapeutics Inc. (GALT)
NasdaqCM · USD · Healthcare · Biotechnology
$3.19 (+0.00%) as of
Key statistics
- Market cap
- 321.71M
- Forward P/E
- -1.90
- EPS (TTM)
- -0.4300
- Dividend yield
- 0.00%
- 52-week range
- 2.0300 – 7.1300
- Beta
- 0.38
- Profit margin
- 0.00%
- Analyst target
- $11.00
- Volume
- 164.39k
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Norcross, GA, United States
- Employees
- 9
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.